Drug Profile
Aldoxorubicin - ImmunityBio
Alternative Names: Aldoxorubicin hydrochloride; DOXO-EMCH; Doxorubicin-6-maleimidocaproyl hydrazone; INNO-206; Tumour-targeted doxorubicin conjugate - LadRx CorporationLatest Information Update: 28 Jun 2023
Price :
$50
*
At a glance
- Originator KTB Tumorforschungs
- Developer ImmunityBio; LadRx Corporation; NantKwest
- Class Amines; Anthracyclines; Antineoplastics; Cytostatic antibiotics; Doxorubicins; Drug conjugates; Hexanoic acids; Hydrazines; Maleimides; Naphthacenes; Pyrroles; Small molecules
- Mechanism of Action DNA intercalators; Reactive oxygen species stimulants; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Soft tissue sarcoma
- Phase II Glioblastoma; Kaposi's sarcoma; Pancreatic cancer; Small cell lung cancer
- Phase I/II Chondrosarcoma; Colorectal cancer; Osteosarcoma; Solid tumours; Squamous cell cancer; Triple negative breast cancer